Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Senter

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
Dipeptide-based highly potent doxorubicin antibody conjugatesScott C Jeffrey, Minh T Nguyen, Jamie B Andreyka, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 6, 2009
The pharmacologic basis for antibody-auristatin conjugate activityStephen C Alley, Xinqun Zhang, Nicole M Okeley, et al.
Bioconjugate Chemistry|September 21, 2013
Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugationNicole M Okeley, Brian E Toki, Xinqun Zhang, et al.
Angewandte Chemie (International Ed. in English)|December 15, 2016
Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug ConjugatesMatthew R Levengood, Xinqun Zhang, Joshua H Hunter, et al.
Molecular Pharmaceutics|August 2, 2018
Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of CamptothecinsUland Y Lau, Lauren T Benoit, Nicole S Stevens, et al.
Bioconjugate Chemistry|March 5, 2008
Contribution of linker stability to the activities of anticancer immunoconjugatesStephen C Alley, Dennis R Benjamin, Scott C Jeffrey, et al.
Bioconjugate Chemistry|September 18, 2003
Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugatesCraig Beeson, James E Butrynski, Michael J Hart, et al.
Bioconjugate Chemistry|September 23, 2008
Novel peptide linkers for highly potent antibody-auristatin conjugateSvetlana O Doronina, Tim D Bovee, David W Meyer, et al.
Bioconjugate Chemistry|September 18, 2003
Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineeringCharlotte F McDonagh, Kevin S Beam, Gabrielle J S Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigenDangshe Ma, Christine E Hopf, Andrew D Malewicz, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
Dipeptide-based highly potent doxorubicin antibody conjugatesScott C Jeffrey, Minh T Nguyen, Jamie B Andreyka, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 6, 2009
The pharmacologic basis for antibody-auristatin conjugate activityStephen C Alley, Xinqun Zhang, Nicole M Okeley, et al.
Bioconjugate Chemistry|September 21, 2013
Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugationNicole M Okeley, Brian E Toki, Xinqun Zhang, et al.
Angewandte Chemie (International Ed. in English)|December 15, 2016
Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug ConjugatesMatthew R Levengood, Xinqun Zhang, Joshua H Hunter, et al.
Molecular Pharmaceutics|August 2, 2018
Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of CamptothecinsUland Y Lau, Lauren T Benoit, Nicole S Stevens, et al.
Bioconjugate Chemistry|March 5, 2008
Contribution of linker stability to the activities of anticancer immunoconjugatesStephen C Alley, Dennis R Benjamin, Scott C Jeffrey, et al.
Bioconjugate Chemistry|September 18, 2003
Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugatesCraig Beeson, James E Butrynski, Michael J Hart, et al.
Bioconjugate Chemistry|September 23, 2008
Novel peptide linkers for highly potent antibody-auristatin conjugateSvetlana O Doronina, Tim D Bovee, David W Meyer, et al.
Bioconjugate Chemistry|September 18, 2003
Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineeringCharlotte F McDonagh, Kevin S Beam, Gabrielle J S Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigenDangshe Ma, Christine E Hopf, Andrew D Malewicz, et al.
Pageof 9